{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:47:51Z","timestamp":1791906471087,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.medcli.2024.02.011","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T17:23:30Z","timestamp":1724174610000},"page":"S31-S35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"S1","title":["Catastrophic antiphospholipid syndrome: Lessons from the \u201cCAPS Registry\u201d"],"prefix":"10.1016","volume":"163","author":[{"given":"Ignasi","family":"Rodriguez-Pint\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2024.02.011_bib0170","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.02.011_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.medcli.2024.02.011_bib0180","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/0961203312436866","article-title":"CAPS registry","volume":"21","author":"Cervera","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.medcli.2024.02.011_bib0185","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/0961203309106832","article-title":"The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe","volume":"18","author":"Cervera","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.medcli.2024.02.011_bib0190","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2024.02.011_bib0195","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.pcl.2005.01.001","article-title":"Antiphospholipid syndrome","volume":"52","author":"Ravelli","year":"2005","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.medcli.2024.02.011_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2008.10.003","article-title":"The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: compelling evidence","volume":"32","author":"Ortega-Hernandez","year":"2009","journal-title":"J Autoimmun"},{"key":"10.1016\/j.medcli.2024.02.011_bib0205","first-page":"585","article-title":"Catastrophic antiphospholipid syndrome: an orchestra with several musicians","volume":"16","author":"Rodr\u00edguez-Pint\u00f3","year":"2014","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.medcli.2024.02.011_bib0210","first-page":"12","article-title":"The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome \u2013 molecular mimicry?","volume":"27","author":"Asherson","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.medcli.2024.02.011_bib0215","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1182\/blood-2011-01-333617","article-title":"In vivo distribution of \u03b22 glycoprotein I under various pathophysiologic conditions","volume":"118","author":"Agostinis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.02.011_bib0220","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/art.21009","article-title":"Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies","volume":"52","author":"Vega-Ostertag","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2024.02.011_bib0225","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1160\/TH12-03-0212","article-title":"Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome","volume":"109","author":"Bontadi","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medcli.2024.02.011_bib0230","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry","volume":"15","author":"Rodr\u00edguez-Pint\u00f3","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.medcli.2024.02.011_bib0235","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.02.011_bib0240","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrrheum.2010.47","article-title":"Antiphospholipid syndrome: frequency, main causes and risk factors of mortality","volume":"6","author":"Espinosa","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.medcli.2024.02.011_bib0245","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s10067-007-0634-x","article-title":"The role of malignancies in patients with catastrophic anti-phospholipid (Asherson's) syndrome","volume":"26","author":"Miesbach","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.medcli.2024.02.011_bib0250","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s11910-022-01228-0","article-title":"Neurologic manifestations of catastrophic antiphospholipid syndrome","volume":"22","author":"Mustafa","year":"2022","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.medcli.2024.02.011_bib0255","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jamadermatol.2022.5221","article-title":"Cutaneous involvement in catastrophic antiphospholipid syndrome in a multicenter cohort of 65 patients","volume":"159","author":"Dupr\u00e9","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.medcli.2024.02.011_bib0260","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/BOR.0000000000000426","article-title":"The catastrophic antiphospholipid syndrome in children","volume":"29","author":"Go","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.medcli.2024.02.011_bib0265","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.02.011_bib0270","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11926-014-0482-z","article-title":"in the context of other thrombotic microangiopathies","volume":"17","author":"Rodr\u00edguez-Pint\u00f3","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.medcli.2024.02.011_bib0275","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.medcli.2024.02.011_bib0280","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/ard.2004.025759","article-title":"Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome","volume":"64","author":"Cervera","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2024.02.011_bib0285","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1177\/0961203309345738","article-title":"Common infectious agents\u2019 prevalence in antiphospholipid syndrome","volume":"18","author":"Zinger","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.medcli.2024.02.011_bib0290","first-page":"355","article-title":"Anti-phospholipid antibodies and thrombotic thrombocytopenic purpura","volume":"5","author":"Montecucco","year":"1987","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.medcli.2024.02.011_bib0295","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000044936","article-title":"Anticardiolipin antibodies in classic pediatric hemolytic\u2013uremic syndrome: a possible pathogenic role","volume":"78","author":"Ardiles","year":"1998","journal-title":"Nephron"},{"key":"10.1016\/j.medcli.2024.02.011_bib0300","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.medcli.2024.02.011_bib0305","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/0885066606287041","article-title":"Catastrophic antiphospholipid syndrome","volume":"21","author":"Vora","year":"2006","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.medcli.2024.02.011_bib0310","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/rheumatology\/key082","article-title":"The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients","volume":"57","author":"Rodr\u00edguez-Pint\u00f3","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.medcli.2024.02.011_bib0315","first-page":"346","article-title":"The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus","volume":"34","author":"Bayraktar","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.medcli.2024.02.011_bib0320","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive an\u00e1lisis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.medcli.2024.02.011_bib0325","doi-asserted-by":"crossref","first-page":"103055","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the \u201cCAPS Registry\u201d","volume":"21","author":"L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.medcli.2024.02.011_bib0330","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.62.6.530","article-title":"Long term outcome of catastrophic antiphospholipid syndrome survivors","volume":"62","author":"Erkan","year":"2003","journal-title":"Ann Rheum Dis"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324001581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324001581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T23:51:28Z","timestamp":1726617088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775324001581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":33,"alternative-id":["S0025775324001581"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2024.02.011","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Catastrophic antiphospholipid syndrome: Lessons from the \u201cCAPS Registry\u201d","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2024.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}